Optimal duration of antibiotic treatment in Gram-negative infections

Current Opinion in Infectious Diseases - Tập 31 Số 6 - Trang 606-611 - 2018
Jan J. De Waele1,2,3, Ignacio Martín‐Loeches4
1Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium
2fax: +32 93 32 49 95
3to Jan J. De Waele, MD, PhD, Department of Critical Care Medicine, Ghent University Hospital, C. Heymanslaan 10, 9000 Gent, Belgium. Tel: +32 93 32 62 19
4Multidisciplinary Intensive Care Research Organization (MICRO), Department of Intensive Care Medicine, St. James’s Hospital, Dublin, Ireland

Tóm tắt

Purpose of review Whilst many guidelines recommend limiting the use of antibiotics because of the increase in antimicrobial resistance (AMR), this strategy becomes challenging when dealing with severe infections in critically ill patients. Moreover, some Gram-negative bacilli (GNB) can exhibit mechanisms of resistance that make the patient more vulnerable to recurrence of infections. We reviewed recent data on the optimal duration of antibiotic therapy in these patients. Recent findings Apart from having no additional clinical benefit at a certain point after initiation, antibiotics might have negative effects. Prolonged antibiotic exposure has been associated to development of AMR and represents a strong reason to avoid long courses of antibiotic therapy in GNB infections. Recent data suggest that also patients with severe infections, in whom source control is adequate, can be managed with short-course antibiotic therapy. Summary The optimal duration of antibiotic therapy depends on many factors, but overall, many infections in the critically ill can be treated with short-course antibiotic therapy (7 days or less). The integration of signs of resolution, biomarkers, clinical judgment, and microbiologic eradication might help to define this optimal duration in patients with life-threatening infections caused by GNB.

Từ khóa


Tài liệu tham khảo

Rice, 2008, The Maxwell Finland lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile, Clin Infect Dis, 46, 491, 10.1086/526535

Meads, 1945, Treatment of pneumococcal pneumonia with penicillin, New Engl J Med, 232, 747, 10.1056/NEJM194506282322601

De Waele, 2018, Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multidrug resistance, Intensive Care Med, 44, 189, 10.1007/s00134-017-5036-1

Garnacho-Montero, 2017, To which extent can we decrease antibiotic duration in critically ill patients, Expert Rev Clin Pharmacol, 10, 1215, 10.1080/17512433.2017.1369879

Manian, 2009, IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection, Clin Infect Dis, 49, 1770, 10.1086/648113

Nelson, 2017, Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections, Infection, 45, 613, 10.1007/s15010-017-1020-5

Zilahi, 2016, Duration of antibiotic therapy in the intensive care unit, J Thorac Dis, 8, 3774, 10.21037/jtd.2016.12.89

Chastre, 2003, Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial, JAMA, 290, 2588, 10.1001/jama.290.19.2588

Kollef, 2012, A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia, Crit Care, 16, R218, 10.1186/cc11862

Harris, 2017, Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition, Clin Microbiol Infect, 23, 533, 10.1016/j.cmi.2016.10.023

Martin-Loeches, 2017, Focus on infection and sepsis, Intensive Care Med, 43, 867, 10.1007/s00134-017-4787-z

American, 2005, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST

Torres, 2017, International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT), Eur Respir J, 50, 10.1183/13993003.00582-2017

Kalil, 2016, Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin Infect Dis, 63, e61, 10.1093/cid/ciw353

Waele, 2018, What every intensivist should know about the management of peritonitis in the intensive care unit, Rev Bras Ter Intensiva, 30, 9, 10.5935/0103-507X.20180007

Montravers, 2018, Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial, Intensive Care Med, 44, 300, 10.1007/s00134-018-5088-x

Hassinger, 2017, Longer-duration antimicrobial therapy does not prevent treatment failure in high-risk patients with complicated intra-abdominal infections, Surg Infect (Larchmt), 18, 659, 10.1089/sur.2017.084

Rattan, 2016, Percutaneously drained intra-abdominal infections do not require longer duration of antimicrobial therapy, J Trauma Acute Care Surg, 81, 108, 10.1097/TA.0000000000001019

Huang, 2017, Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis, Ann Intensive Care, 7, 114, 10.1186/s13613-017-0338-6

Ankomah, 2017, Serial procalcitonin levels correlate with microbial etiology in hospitalized patients with pneumonia, Open Forum Infect Dis, 4, S351, 10.1093/ofid/ofx163.846

Wongsurakiat, 2018, Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative Gram-negative bacilli infection, Ther Adv Respir Dis, 12, 1753466618760134, 10.1177/1753466618760134

Huttner, 2017, PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia, BMJ Open, 7, e017996, 10.1136/bmjopen-2017-017996

Azam, 2018, Updates on the pathogenicity status of Pseudomonas aeruginosa, Drug Discov Today

Siempos, 2008, Frequency and predictors of ventilator-associated pneumonia recurrence: a meta-analysis, Shock, 30, 487, 10.1097/SHK.0b013e31816f1f7c

Planquette, 2013, Pseudomonas aeruginosa ventilator-associated pneumonia. predictive factors of treatment failure, Am J Respir Crit Care Med, 188, 69, 10.1164/rccm.201210-1897OC

Bouglé, 2017, Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study, Trials, 18, 37, 10.1186/s13063-017-1780-3

Royer, 2018, Shorter versus longer courses of antibiotics for infection in hospitalized patients: a systematic review and meta-analysis, J Hosp Med, 13, 336, 10.12788/jhm.2905

Armand-Lefèvre, 2013, Emergence of imipenem-resistant Gram-negative bacilli in intestinal flora of intensive care patients, Antimicrob Agents Chemother, 57, 1488, 10.1128/AAC.01823-12

Thông tin
Thông tin xuất bản

Current Opinion in Infectious Diseases

Tập 31 Số 6

606-611

Thông tin tác giả